Volato Group, Inc. (SOAR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Volato Group, Inc. on June 8, 2026, reporting events occurring on June 7, 2026. The Company, an emerging growth company incorporated in Delaware, is focused on AI infrastructure acquisition opportunities. The filing details a material definitive agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Class A Common Stock.
- Shares Issued: 6,500,000 shares.
- Price Per Share: $0.34.
- Gross Proceeds: Approximately $2.21 million (before transaction fees and offering expenses).
- Investors: Catheter Precision, Inc. (NYSE American: VTAK) and certain institutional investors.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The filing text does not provide a clear value for these operational metrics.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement on June 7, 2026. Key terms include:
- Closing Conditions: The offering is subject to NYSE American LLC approval of a supplemental listing application and the delivery of freely tradeable third-party securities to Catheter Precision, Inc.
- Lock-up Covenant: The Company agreed not to enter into any Variable Rate Transactions for nine months from the Effective Date, subject to exceptions.
- Registration Rights: The Company must file a registration statement for the resale of shares within 10 calendar days of the agreement and use commercially reasonable efforts to declare it effective promptly.
- Exemption: The sale was conducted under Section 4(a)(2) of the Securities Act and Regulation D without general solicitation.
Outlook, Risks, and Management Commentary
Management indicated a strategic focus on AI infrastructure acquisition opportunities following the capital raise. The filing includes standard forward-looking statement disclaimers regarding future performance. Specific risks highlighted include:
- Uncertainty regarding the effect of a Reverse Stock Split on the trading price of Common Stock.
- Risks associated with maintaining compliance with continued listing requirements.
- General economic, competitive, and regulatory factors beyond the Company's control.
Investor Verification Checklist
- Verify the satisfaction of closing conditions, specifically the NYSE American LLC supplemental listing approval.
- Confirm the delivery of the third-party securities required by Catheter Precision, Inc. as a closing condition.
- Monitor the filing and effectiveness of the registration statement for the resale of the 6.5 million shares.
- Review the Company's most recent Form 10-K for fiscal year ended December 31, 2025, for historical financial context not included in this 8-K.
- Assess the impact of the 6.5 million new shares on existing shareholder dilution.